Altravax receives two SBIR grants for antibody-inducing vaccines research on HIV-1 Altravax, Inc. Announced today that it has been awarded two SBIR grants totaling $1 answer all your questions .2 million from the NIH’s National Institute of Allergy and Infectious Illnesses for research on antibody-inducing vaccines for HIV-1. A 2009 report from the US has estimated the total number of people living with AIDS is currently at over 30 million. The existence of numerous virus strains and the ongoing changing character of the virus is one of the major difficulties facing the advancement of vaccines for HIV/AIDS.
Their findings are published on-line in the Journal of Neurotoxicity Study. They shall appear in the May print edition. Their outcomes clarify how small proteins called amyloid-beta peptides damage mind cell membranes, enabling extra calcium ions to enter the neurons. An ion can be an electrically-billed particle. An ion imbalance in a cell can result in its suicide. Amyloid-beta peptides will be the prime suspects for leading to cell loss of life in Alzheimer’s, although additional mechanisms is to blame also. The disease isn’t well understood. The experts confirmed evidence discovered by others that amyloid-beta peptides prick pores into mind cell membranes, opening stations where calcium ions can hurry in. This is one mechanism the field experienced contemplated, but other evidence suggested a different situation.